Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Double Blind, Placebo-controlled Phase II/III Study Evaluating the Efficacy of Rituximab in the Prevention of Relapse of Calcineurin Inhibitors Dependent Idiopathic Nephrotic Syndrome of Childhood

NCT01268033 is registered in ClinicalTrials.gov with University Hospital, Limoges as lead sponsor.

NCT NCT01268033
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01268033 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Double Blind, Placebo-controlled Phase II/III Study Evaluating the Efficacy of Rituximab in the Prevention of Relapse of Calcineurin Inhibitors Dependent Idiopathic Nephrotic Syndrome of Childhood
Lead sponsor
University Hospital, Limoges
Phase
Phase 2/3
Overall status
Completed
Start date
December 31, 2010
Completion date
May 31, 2014
Enrollment
26 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

childhood idiopathic nephrotic syndrome